TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2008

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Maria R Baer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.